Trinity Participates in RACE Cancer Foundation Boston 5K to Support Fight Against Cancer

Trinity employees ran and power-walked to support the battle against cancer at the RACE Cancer Foundation 5K on August 10th in Boston. RACE programs create opportunities to reduce and detect cancer through education, prevention, and screening measures. 100 percent of funds raised at RACE running events benefit organizations such as the Leukemia & Lymphoma Society, Target Cancer Foundation and the Multiple Myeloma Research Foundation. Trinity had a great time meeting other members of the Greater Boston community who are dedicated to helping in the fight against cancer.

Trinity Partners Gives Back at the Community Day Center of Waltham

Last week, Trinity employees spent an afternoon organizing, menu planning, cooking and serving lunch to individuals at the Community Day Center of Waltham. The Day Center, a not-for-profit organization, provides a warm, welcoming place and services for people who are homeless and those who may feel alone and isolated. Trinity encourages all employees to dedicate a portion of their time to volunteer work in the local community.

Pharmaceutical Commerce Speaks with Herman Sanchez About the Evolving Oncology Market

Partner Herman Sanchez recently spoke with Pharmaceutical Commerce about the cancer market and how immune-oncology is revolutionizing the space. Learn more about the rapidly evolving industry here: http://pharmaceuticalcommerce.com/brand-marketing-communications/new-science-energizes-cancer-market/

Trinity Partners Identifies Value Proposition of Most Expensive Drugs Approved by the FDA from 2014-2016

Trinity Partners today, in tandem with the 22nd Annual International ISPOR Meeting, announced the results of a whitepaper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the costliest drugs to the healthcare system approved by the FDA from 2014-2016 in order to understand the interaction between value and price.  In this industry analysis, Trinity reveals the factors that appear to allow some drugs a higher price point than others and addresses key questions including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for?

Download the whitepaper here: http://bit.ly/2qQyKso

Trinity Partners Attends Life Science Cares Impact Breakfast

Trinity team members attended MassBio’s Life Science Cares Impact Breakfast on May 16, celebrating the industry’s commitment to ending poverty in greater Boston with over 500 life science leaders attended the event. Life Science Cares is a collective effort of the life science industry to eliminate the impact of poverty on our neighbors in the greater Boston area. Through uniting the human and financial resources of life science companies and industry leaders, we support service organizations that do the best work in fighting poverty in our community. Check out our team who attended the gathering!

Trinity Partners Experts to Attend Veeva Summit 2017

Trinity Partners, a leading global life sciences consulting firm, announced that John Gillis will attend Veeva Systems’ 2017 Global Commercial & Medical Summit in Philadelphia from May 7-9. Deemed the “industry’s largest event,” our employees are looking forward to networking with over 1,200 life science professionals and learning more about commercial and medical affairs. Read about the conference here: http://bit.ly/1GjpEWp.

Trinity Partners to Present at European Association of Dermato Oncology (EADO)

Trinity Partners, a leading global life sciences consulting firm, announced that Senior Associate Consultant Zahra Al-Khateeb will present a poster from our work with Array BioPharma at the 13th Congress of the EADO in Athens, Greece from May 3-6, 2017. The event will cover all aspects of melanoma and skin cancers, anywhere from epidemiology, diagnosis and prevention to the results of the latest therapeutic trials in advanced tumors. Zahra will present a poster on the current mutation testing approaches in metastatic melanoma and unmet need in the NRAS+ patient population in the U.S. Learn more about the conference: https://www.erasmus.gr/microsites/1063